FDA clears Johnson & Johnson hepatitis C drug

FDA clears Johnson & Johnson hepatitis C drug

WASHINGTON — Federal regulators on Friday approved a new drug from Johnson & Johnson for use in treating chronic hepatitis C infections. The U.S. Food and Drug Administration said it approved the drug, a protease inhibitor that blocks a protein needed 

4
Like
Save

Comments

Write a comment

*